Y-Biologics, Inc. (KOSDAQ:338840)
22,800
-900 (-3.80%)
At close: Feb 6, 2026
Y-Biologics Revenue
Y-Biologics had revenue of 892.40M KRW in the quarter ending September 30, 2025, a decrease of -72.46%. This brings the company's revenue in the last twelve months to 3.61B, down -30.96% year-over-year. In the year 2024, Y-Biologics had annual revenue of 5.76B with 65.64% growth.
Revenue (ttm)
3.61B
Revenue Growth
-30.96%
P/S Ratio
95.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
346.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.76B | 2.28B | 65.64% |
| Dec 31, 2023 | 3.48B | -671.48M | -16.18% |
| Dec 31, 2022 | 4.15B | -696.78M | -14.37% |
| Dec 31, 2021 | 4.85B | -1.88B | -27.99% |
| Dec 31, 2020 | 6.73B | 5.38B | 399.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GC Cell | 170.13B |
| HansBiomed | 89.78B |
| ISU Abxis | 66.39B |
| NIBEC | 32.96B |
| Genome & Company | 25.95B |
| S.Biomedics | 16.96B |
| Prestige Biologics | 13.36B |
| Vaxcell-Bio Therapeutics | 1.90B |